Fig. 3

a Proliferation of HuCCT-1 and TFK-1 under treatment with MPA, *p <0.05, unpaired t-test. Tumour cells were treated with DMEM plus 10 % FCS containing different concentrations of MPA. Cell viability was measured after 24, 48 and 96 h using Crystal violet assay (blue line: 24 h of treatment with different drug concentrations of MPA, reed line: blue line: 48 h of treatment with different drug concentrations of MPA, green line: 96 h of treatment with different drug concentrations of MPA). b Proliferation of HuCCT-1 and TFK-1 under treatment with Everolimus, *p <0.05, unpaired t-test. Tumour cells were treated with DMEM plus 10 % FCS containing different concentrations of Everolimus. Cell viability was measured after 24, 48 and 96 h using Crystal violet assay (blue line: 24 h of treatment with different drug concentrations of Everolimus, reed line: blue line: 48 h of treatment with different drug concentrations of Everolimus, green line: 96 h of treatment with different drug concentrations of Everolimus). c Proliferation of HuCCT-1 and TFK-1 under treatment with CSA. Tumour cells were treated with DMEM plus 10 % FCS containing different concentrations of CSA (blue line: 24 h of treatment with different drug concentrations of CSA, reed line: blue line: 48 h of treatment with different drug concentrations of CSA, green line: 96 h of treatment with different drug concentrations of CSA). d Proliferation of CAFs under treatment with MPA, *p <0.05, unpaired t-test. CAFs were treated with DMEM plus 10 % FCS containing different concentrations of MPA. Cell viability was measured after 24, 48 and 96 h using Crystal violet assay (blue line: 24 h of treatment with different drug concentrations of MPA, reed line: blue line: 48 h of treatment with different drug concentrations of MPA, green line: 96 h of treatment with different drug concentrations of MPA). e Proliferation of CAFs under treatment with Everolimus, *p <0.05, unpaired t-test. CAFs were treated with DMEM plus 10 % FCS containing different concentrations of Everolimus. Cell viability was measured after 24, 48 and 96 h using Crystal violet assay (blue line: 24 h of treatment with different drug concentrations of Everolimus, reed line: blue line: 48 h of treatment with different drug concentrations of Everolimus, green line: 96 h of treatment with different drug concentrations of Everolimus). f Proliferation of CAFs under treatment with CSA. CAFs were treated with DMEM plus 10 % FCS containing different concentrations of CSA. Cell viability was measured after 24, 48 and 96 h using Crystal violet assay (blue line: 24 h of treatment with different drug concentrations of CSA, reed line: blue line: 48 h of treatment with different drug concentrations of CSA, green line: 96 h of treatment with different drug concentrations of CSA)